These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27881236)

  • 1. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
    Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
    Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox AUC efficacy cutoff and role of pharmacogenetics.
    Allegra S; Cusato J; De Francia S; Massano D; Piga A; D'Avolio A
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1155-7. PubMed ID: 27193993
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
    Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
    Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
    Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
    Lu MY; Lin TH; Chiang PH; Kuo PH; Wang N; Wu WH; Lin KH; Wu TH
    Ther Drug Monit; 2017 Apr; 39(2):185-191. PubMed ID: 28141745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?
    Mattioli F; Puntoni M; Marini V; Fucile C; Milano G; Robbiano L; Perrotta S; Pinto V; Martelli A; Forni GL
    Eur J Haematol; 2015 Apr; 94(4):310-7. PubMed ID: 25081908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five Years of Deferasirox Therapy for Cardiac Iron in β-Thalassemia Major.
    Vlachaki E; Agapidou A; Spanos G; Klonizakis P; Vetsiou E; Mavroudi M; Boura P
    Hemoglobin; 2015; 39(5):299-304. PubMed ID: 26177199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
    Chauzit E; Bouchet S; Micheau M; Mahon FX; Moore N; Titier K; Molimard M
    Ther Drug Monit; 2010 Aug; 32(4):476-81. PubMed ID: 20386360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R; Campus S; Origa R
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E; Christoulas D; Terpos E
    Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
    [No Abstract]   [Full Text] [Related]  

  • 17. Normal pregnancy in a patient with β-thalassaemia major receiving iron chelation therapy with deferasirox (Exjade®).
    Vini D; Servos P; Drosou M
    Eur J Haematol; 2011 Mar; 86(3):274-5. PubMed ID: 21198860
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral iron chelator deferasirox in the treatment of secondary hemochromatosis following bone marrow transplantation in a patient with severe aplastic anemia.
    Quarta A; Melpignano A; Quarta G
    Acta Haematol; 2011; 125(4):219-21. PubMed ID: 21266801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.
    Deugnier Y; Turlin B; Ropert M; Cappellini MD; Porter JB; Giannone V; Zhang Y; Griffel L; Brissot P
    Gastroenterology; 2011 Oct; 141(4):1202-11, 1211.e1-3. PubMed ID: 21741344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.